Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Combined PD-1 and Tim-3 Blockade Improves the in Vitro Anti-Myeloma Activity of T Cells of Patients on Talquetamab

Blood (2024) 144 (Supplement 1): 357.

https://doi.org/10.1182/blood-2024-204929

Published: 2024

Journal Articles

Clinical Outcomes in Black Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 Monumental-1 Study

Blood (2024) 144 (Supplement 1): 3357.

https://doi.org/10.1182/blood-2024-199797

Published: 2024

Journal Articles

Immune Dynamics Associated with Patient Outcomes Identified By Multimodal Single-Cell Analysis in Multiple Myeloma Patients Receiving Talquetamab Monotherapy

Blood (2023) 142 (Supplement 1): 1927.

https://doi.org/10.1182/blood-2023-185308

Published: 2023

Journal Articles

Clinical Outcomes of Subsequent Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 MonumenTAL-1 Study

Blood (2023) 142 (Supplement 1): 2007.

https://doi.org/10.1182/blood-2023-182330

Published: 2023

Journal Articles

Early and Consistent CRS Detection Using Wearable Device for Remote Patient Monitoring Following CAR-T Therapy in Relapsed/Refractory Multiple Myeloma (RRMM): Early Results of an Investigator-Initiated Trial

Blood (2023) 142 (Supplement 1): 1007.

https://doi.org/10.1182/blood-2023-181936

Published: 2023

Journal Articles

Multimodal Single-Cell Transcriptomic and Proteomic Correlatives of Patients Outcomes Following Anti-BCMA Cellular Therapy with Ciltacabtagene Autoleucel (Cilta-cel) in Relapsed Multiple Myeloma

Blood (2023) 142 (Supplement 1): 93.

https://doi.org/10.1182/blood-2023-186395

Published: 2023

Journal Articles

Timing of Vaccination Impacts Serological Response to COVID-19 Myeloma Patients after BCMA-Targeted CAR T

Blood (2023) 142 (Supplement 1): 3350.

https://doi.org/10.1182/blood-2023-184409

Published: 2023

Journal Articles

Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy

Blood (2023) 141 (7): 756–765.

https://doi.org/10.1182/blood.2022017848

Published: 2023

Includes: Supplemental data

Journal Articles

Gain of chr1q Portends Poor Outcomes in Multiple Myeloma Patients Treated with Venetoclax

Alessandro Lagana, Santiago Thibaud, David T. Melnekoff, Paula Restrepo, Violetta Leshchenko, Jonathan McCafferty, Scott Newman, Abbi Kern, David Corrigan, Feras Hantash, Adriana Rossi, Cesar Rodriguez, Larysa Sanchez, Shambavi Richard, Ajai Chari, Hearn J. Cho, Sundar Jagannath, Joshua Richter, Samir Parekh

Blood (2022) 140 (Supplement 1): 4388–4390.

https://doi.org/10.1182/blood-2022-166572

Published: 2022

Journal Articles

Immune Recovery Post BCMA CAR-T: Implications for Infection Prophylaxis and Vaccinations

Shambavi Richard, Guido Lancman, Santiago Thibaud, Ajai Chari, Samir Parekh, Adriana Rossi, Hearn J. Cho, Larysa Sanchez, Joshua Richter, Cesar Rodriguez, Elizabeth Aronson, Karen Louw, Kiah Purcell, Daniel Verina, Juliet Escalon, Sundar Jagannath

Blood (2022) 140 (Supplement 1): 7444–7446.

https://doi.org/10.1182/blood-2022-170404

Published: 2022

Journal Articles

Timing and Nature of Infections in Multiple Myeloma Patients Treated with Anti-BCMA CAR-T Cells

Guido Lancman, Margaret Shyu, Megan Metzger, Kian Parsa, Hearn J. Cho, Samir Parekh, Joshua Richter, Cesar Rodriguez, Adriana Rossi, Larysa Sanchez, Santiago Thibaud, Sundar Jagannath, Ajai Chari, Shambavi Richard

Blood (2022) 140 (Supplement 1): 7198–7199.

https://doi.org/10.1182/blood-2022-163757

Published: 2022

Journal Articles

Salvage with Sequential T Cell Redirection for Myeloma Patients Who Have Previously Progressed on T Cell Directed Therapy Is Associated with Significant Cellular Activation of the Immune Microenvironment

Adolfo Aleman, Ariel Kogan Zajdman, Yogita Ghodke-Puranik, Bhaskar Upadhyaya, Tarek H. Mouhieddine, Oliver Van Oekelen, Larysa Sanchez, Shambavi Richard, Adriana Rossi, Joshua Richter, Hearn J. Cho, Cesar Rodriguez, Ajai Chari, Sundar Jagannath, Samir Parekh

Blood (2022) 140 (Supplement 1): 4193–4195.

https://doi.org/10.1182/blood-2022-169538

Published: 2022

Journal Articles

Infections and Severe Hypogammaglobulinemia in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

Guido Lancman, Kian Parsa, Cesar Rodriguez, Joshua Richter, Hearn J. Cho, Samir Parekh, Shambavi Richard, Adriana Rossi, Larysa Sanchez, Santiago Thibaud, Sundar Jagannath, Ajai Chari

Blood (2022) 140 (Supplement 1): 10073–10074.

https://doi.org/10.1182/blood-2022-163733

Published: 2022

Journal Articles

Comparative Effectiveness of Lenalidomide/Dexamethasone-Based Triplet Regimens for Treatment of Relapsed and/or Refractory Multiple Myeloma in Subgroups Defined By Cytogenetic Risk

Larysa Sanchez, Mu Cheng, Dasha Cherepanov, Maral DerSarkissian, Dawn Marie Stull, Fei Huang, Annalise Hilts, Justin Chun, Mei Sheng Duh, Sikander Ailawadhi

Blood (2022) 140 (Supplement 1): 4308–4309.

https://doi.org/10.1182/blood-2022-156320

Published: 2022

Journal Articles

Extramedullary Relapse Post CAR-T

Shambavi Richard, Guido Lancman, Adriana Rossi, Ajai Chari, Samir Parekh, Larysa Sanchez, Cesar Rodriguez, Hearn J. Cho, Joshua Richter, Santiago Thibaud, Kiah Purcell, Elizabeth Aronson, Daniel Verina, Juliet Escalon, Karen Louw, Sundar Jagannath

Blood (2022) 140 (Supplement 1): 4301–4302.

https://doi.org/10.1182/blood-2022-170119

Published: 2022

Journal Articles

Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy

Blood (2022) 140 (Supplement 1): 614–616.

https://doi.org/10.1182/blood-2022-165646

Published: 2022

Journal Articles

Clinical Outcomes and Treatment Strategies for Relapsed/Refractory Myeloma Patients after Relapse on BCMA-Targeted CAR T

Oliver Van Oekelen, Tarek H. Mouhieddine, Darren Pan, Megan Metzger, Sarita Agte, Adolfo Aleman, David T. Melnekoff, Guido Lancman, Alessandro Lagana, Shambavi Richard, Larysa Sanchez, Joshua Richter, Hearn Jay Cho, Ajai Chari, Sundar Jagannath, Samir Parekh

Blood (2021) 138 (Supplement 1): 2704.

https://doi.org/10.1182/blood-2021-152243

Published: 2021

Journal Articles

Characterization and Management of Oral and Dermatological Toxicities in Patients Receiving the CD3 X GPRC5D Bispecific Antibody Talquetamab (JNJ-64407564) for the Treatment of Relapsed and/or Refractory Multiple Myeloma

Stefania Stefania Mancia, Annamaria Farrell, Karen Louw, Erika Florendo, Elizabeth Aronson, Kiah Purcell, Donna D Catamero, Juliet Escalon, Joanne Thomas, Annel Aponte, Angela Lamb, Diana Kirke, Aimee Lucas, Sundar Jagannath, Hearn Jay Cho, Samir Parekh, Joshua Richter, Larysa Sanchez, Ajai Chari

Blood (2021) 138 (Supplement 1): 1658.

https://doi.org/10.1182/blood-2021-153817

Published: 2021

Journal Articles

Clinical Outcomes of Relapsed/Refractory Multiple Myeloma Patients Following Treatment with Bispecific Antibodies (BiAbs)

Tarek H. Mouhieddine, Oliver Van Oekelen, Darren Pan, Sarita Agte, Adolfo Aleman, David T. Melnekoff, Guido Lancman, Santiago Thibaud, Larysa Sanchez, Shambavi Richard, Joshua Richter, Hearn Jay Cho, Ajai Chari, Sundar Jagannath, Samir Parekh

Blood (2021) 138 (Supplement 1): 821.

https://doi.org/10.1182/blood-2021-151585

Published: 2021

Journal Articles

Pathogenic Germline Variants in Multiple Myeloma

Santiago Thibaud, Aaron Etra, Ryan Subaran, Zachry Soens, Scott Newman, Rong Chen, Ajai Chari, Hearn Jay Cho, Sundar Jagannath, Deepu Madduri, David T. Melnekoff, Shambavi Richard, Joshua Richter, Larysa Sanchez, Kuan-lin Huang, Alessandro Lagana, Samir Parekh, Kenan Onel

Blood (2021) 138 (Supplement 1): 399.

https://doi.org/10.1182/blood-2021-151495

Published: 2021

NARROW

Combined PD-1 and Tim-3 Blockade Improves the in Vitro Anti-Myeloma Activity of T Cells of Patients on Talquetamab

Clinical Outcomes in Black Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 Monumental-1 Study

Immune Dynamics Associated with Patient Outcomes Identified By Multimodal Single-Cell Analysis in Multiple Myeloma Patients Receiving Talquetamab Monotherapy

Clinical Outcomes of Subsequent Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 MonumenTAL-1 Study

Early and Consistent CRS Detection Using Wearable Device for Remote Patient Monitoring Following CAR-T Therapy in Relapsed/Refractory Multiple Myeloma (RRMM): Early Results of an Investigator-Initiated Trial

Multimodal Single-Cell Transcriptomic and Proteomic Correlatives of Patients Outcomes Following Anti-BCMA Cellular Therapy with Ciltacabtagene Autoleucel (Cilta-cel) in Relapsed Multiple Myeloma

Timing of Vaccination Impacts Serological Response to COVID-19 Myeloma Patients after BCMA-Targeted CAR T

Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy

Gain of chr1q Portends Poor Outcomes in Multiple Myeloma Patients Treated with Venetoclax

Immune Recovery Post BCMA CAR-T: Implications for Infection Prophylaxis and Vaccinations

Timing and Nature of Infections in Multiple Myeloma Patients Treated with Anti-BCMA CAR-T Cells

Salvage with Sequential T Cell Redirection for Myeloma Patients Who Have Previously Progressed on T Cell Directed Therapy Is Associated with Significant Cellular Activation of the Immune Microenvironment

Infections and Severe Hypogammaglobulinemia in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

Comparative Effectiveness of Lenalidomide/Dexamethasone-Based Triplet Regimens for Treatment of Relapsed and/or Refractory Multiple Myeloma in Subgroups Defined By Cytogenetic Risk

Extramedullary Relapse Post CAR-T

Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy

Clinical Outcomes and Treatment Strategies for Relapsed/Refractory Myeloma Patients after Relapse on BCMA-Targeted CAR T

Characterization and Management of Oral and Dermatological Toxicities in Patients Receiving the CD3 X GPRC5D Bispecific Antibody Talquetamab (JNJ-64407564) for the Treatment of Relapsed and/or Refractory Multiple Myeloma

Clinical Outcomes of Relapsed/Refractory Multiple Myeloma Patients Following Treatment with Bispecific Antibodies (BiAbs)

Pathogenic Germline Variants in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only